



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

1632  
24  
5-21-02  
p.2.  
**RECEIVED**

MAY 13 2002

TECH CENTER 1600/2900

**Applicant:** Charles L. Sawyers et al.

**Serial No.:** 10/066,266

**COPY OF PAPERS  
ORIGINALLY FILED**

**Filed:** January 30, 2002

**Docket:** 30435.53USD4

**Title:** METHODS OF ASSESSING THE EFFECT OF A GENE OF INTEREST ON HUMAN  
PROSTATE CANCER PROGRESSION

CERTIFICATE UNDER 37 CFR 1.8

I hereby certify that this paper or fee is being deposited with the United States Postal as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231 on April 30, 2002.

By:   
Name: Richelle Ann Domingo

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:


We are transmitting herewith the attached:

- ☒ Transmittal sheet, in duplicate, containing Certificate under 37 CFR 1.8.
- ☒ Information Disclosure Statement (37 C.F.R. §1.97 (d))
- ☒ Form 1449 (Information Disclosure Statement)
- ☒ Return postcard

Please charge any additional fees or credit overpayment to Deposit Account No. 50-0306. A duplicate of this sheet is enclosed.

**MANDEL & ADRIANO**

35 No. Arroyo Parkway, Suite 60  
Pasadena, California 91103  
(626)395-7801

By:   
Name: Sarah B. Adriano  
Reg. No.: 34,470  
Initials: SBA



COPY OF PAPERS  
ORIGINALLY FILED

RECEIVED

MAY 13 2002


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

**Applicant:** Charles L. Sawyers, et al. **Examiner:** Not yet assigned  
**Serial No.:** 10/066,266 **Group Art Unit:** 1632  
**Filed:** January 30, 2002 **Docket No.:** 30435.53USD4  
**Title:** METHODS OF ASSESSING THE EFFECT OF A GENE OF INTEREST  
ON HUMAN PROSTATE CANCER PROGRESSION

CERTIFICATE UNDER 37 CFR 1.8:

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on April 30, 2002.

By:   
Richelle Ann Domingo

**INFORMATION DISCLOSURE STATEMENT (37 C.F.R. §1.97(d))**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner. They are as follows:

- Liu, A.Y., et al., "Prostatic Cell Lineage Markers: Emergence of BCL2<sup>+</sup> Cells of Human Prostate Cancer Xenograft LuCaP 23 Following Castration," *Int. J. Cancer*, 65:85-89 (1996).
- Lubaroff, D.M., et al., "Survival of Human Prostate Carcinoma, Benign Hyperplastic Prostate Tissues, and IL-2 Activated Lymphocytes in SCID Mice," *The Prostate*, 27:32-41 (1995).
- Wainstein, M.A., et al., "CWR22: Androgen-Dependent Xenograft Model Derived from a Primary Human Prostatic Carcinoma," *Cancer Research*, 54:6049-6052 (1994).
- Pretlow, T.G., et al., "Xenograft of Primary Human Prostatic Carcinoma," *Journal of the National Cancer Institute*, 85(5):394-398 (1993).

- Pretlow, T.G., et al., "Transplantation of Human Prostatic Carcinoma into Nude Mice in Matrigel," *Cancer Research*, 51:3814-3817 (1991).
- Perez-Stable, et al., *Cancer Research*, Vol. 57, Pages 900-906. (March 1, 1997).
- Sato, et al., *Journal of Urology*, Vol. 155: 5, Page 338A (May 4, 1996).
- van Weerden, et al., *American Journal of Pathology*, Vol. 149: 3, Pages 1055-1062. (September 1996).

This statement should be considered because it is submitted before the mailing date of the first Office Action on the merits. The present application is a divisional application of U.S. Serial No. 09/567,202, filed May 8, 2000. The art cited in the enclosed PTO Form 1449 were previously of record in the parent application, i.e., U. S. Serial No. 09/567, 202 and are not provided herewith in accordance with 37 C.F.R. §1.98(d).

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.

No fees are due in connection with the filing of this IDS. If, however, a fee is deemed necessary, please charge any additional fees to Deposit Account No. 50-0306.

Respectfully submitted,

Sarah B. Adriano

Sarah B. Adriano  
Registration No. 34,470  
Attorney for Applicants  
Mandel & Adriano  
35 N. Arroyo Parkway, Suite 60  
Pasadena, CA 91103  
(626) 395-7801

COPY OF PAPERS  
ORIGINALLY FILED

RECEIVED

Sheet 1 of 1

FORM 1449\*

INFORMATION DISCLOSURE STATEMENT

Docket Number

30435.53USD1

Application Number

09/567, 20

Applicant

(Use several sheets if necessary)

Filing Date

May 8, 2000

Group Art Unit

1632

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

TNT

Liu, A. Y., et al., "Prostatic Cell Lineage Markers: Emergence of BCL2<sup>+</sup> Cells of Human Prostate Cancer Xenograft LuCaP 23 Following Castration," *Int. J. Cancer*, 65:85-89 (1996).

Lubaroff, D. M., et al., "Survival of Human Prostate Carcinoma, Benign Hyperplastic Prostate Tissues, and IL-2-Activated Lymphocytes in SCID Mice," *The Prostate*, 27:32-41 (1995).

Wainstein, M. A., et al., "CWR22: Androgen-Dependent Xenograft Model Derived from a Primary Human Prostatic Carcinoma," *Cancer Research*, 54:6049-6052 (1994).

Pretlow, T. G., et al., "Xenografts of Primary Human Prostatic Carcinoma," *Journal of the National Cancer Institute*, 85(5):394-398 (1993).

Pretlow, T. G., et al., "Transplantation of Human Prostatic Carcinoma into Nude Mice in Matrigel," *Cancer Research*, 51:3814-3817 (1991).

Perez-Stable et al., *Cancer Research*, Vol. 57, Pages 900-906. (March 1, 1997).

Sato et al., *Journal of Urology*, Vol. 155: 5, Page 338A. (May 4, 1996).

TNT

van Weerden et al., *American Journal of Pathology*, Vol. 149: 3, Pages 1055-1062. (September 1996).

RECEIVED

MAY 13 2002

TECH CENTER 1600/2900

EXAMINER

Thaie 2.2

DATE CONSIDERED

9/25/01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

\*Substitute Disclosure Statement Form (PTO-1449)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE